Drug
68-Ga PSMA11
68-Ga PSMA11 is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
200%(2 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_1
2
67%
Ph phase_2
1
33%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Terminated1
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
terminated133%
completed133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_1
PSMA PET Response Guided SabR in High Risk Pca
NCT06044857
terminatedphase_2
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
NCT04264208
completedphase_1
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
NCT03949517
Clinical Trials (3)
Showing 3 of 3 trials
NCT06044857Phase 1
PSMA PET Response Guided SabR in High Risk Pca
NCT04264208Phase 2
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
NCT03949517Phase 1
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3